医学
麻醉
苯肾上腺素
优势比
临床终点
随机对照试验
置信区间
不利影响
外科
血压
内科学
作者
Matthieu Legrand,Rishi Kothari,Nicholas Fong,Nandini Palaniappa,David H. Boldt,Lee-lynn Chen,Philip A. Kurien,Eilon Gabel,Jillene Sturgess-DaPrato,Michael O. Harhay,Romain Pirracchio,Michael P. Bokoch
标识
DOI:10.1016/j.bja.2023.02.004
摘要
Intraoperative hypotension is associated with postoperative complications. The use of vasopressors is often required to correct hypotension but the best vasopressor is unknown.A multicentre, cluster-randomised, crossover, feasibility and pilot trial was conducted across five hospitals in California. Phenylephrine (PE) vs norepinephrine (NE) infusion as the first-line vasopressor in patients under general anaesthesia alternated monthly at each hospital for 6 months. The primary endpoint was first-line vasopressor administration compliance of 80% or higher. Secondary endpoints were acute kidney injury (AKI), 30-day mortality, myocardial injury after noncardiac surgery (MINS), hospital length of stay, and rehospitalisation within 30 days.A total of 3626 patients were enrolled over 6 months; 1809 patients were randomised in the NE group, 1817 in the PE group. Overall, 88.2% received the assigned first-line vasopressor. No drug infiltrations requiring treatment were reported in either group. Patients were median 63 yr old, 50% female, and 58% white. Randomisation in the NE group vs PE group did not reduce readmission within 30 days (adjusted odds ratio=0.92; 95% confidence interval, 0.6-1.39), 30-day mortality (1.01; 0.48-2.09), AKI (1.1; 0.92-1.31), or MINS (1.63; 0.84-3.16).A large and diverse population undergoing major surgery under general anaesthesia was successfully enrolled and randomised to receive NE or PE infusion. This pilot and feasibility trial was not powered for adverse postoperative outcomes and a follow-up multicentre effectiveness trial is planned.NCT04789330 (ClinicalTrials.gov).
科研通智能强力驱动
Strongly Powered by AbleSci AI